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PTEN dysfunction plays a crucial role in the patho-
genesis of hereditary and sporadic cancers. Here,
we show that PTEN homodimerizes and, in this
active conformation, exerts lipid phosphatase activ-
ity on PtdIns(3,4,5)P3. We demonstrate that catalyti-
cally inactive cancer-associated PTEN mutants
heterodimerize with wild-type PTEN and constrain
its phosphatase activity in a dominant-negative
manner. To study the consequences of homo- and
heterodimerization of wild-type and mutant PTEN
in vivo, we generated Pten knockin mice harboring
two cancer-associated PTEN mutations (PtenC124S
and PtenG129E). Heterozygous PtenC124S/+ and
PtenG129E/+ cells and tissues exhibit increased sensi-
tivity to PI3-K/Akt activation compared to wild-type
and Pten+/ counterparts, whereas this difference
is no longer apparent between PtenC124S/ and
Pten/ cells. Notably, Pten KI mice are more tumor
prone and display features reminiscent of complete
Pten loss. Our findings reveal that PTEN loss
and PTEN mutations are not synonymous and define
a working model for the function and regulation
of PTEN.INTRODUCTION
Phosphatase and tensin homolog deleted on chromosome ten
(PTEN) is a tumor suppressor frequently lost or mutated in
human cancers and in a number of tumor syndromes, referred
to as ‘‘PTEN hamartoma tumor syndromes’’ (PHTS), which
include Cowden disease (CD) and Bannayan-Zonana syndrome
(Hollander et al., 2011).
To study the consequences of Pten loss in vivo, we and others
generatedanimalmodelswithpartial and total lossofPten (DiCris-
tofano et al., 1998; Podsypanina et al., 1999; Suzuki et al., 1998).
Total Pten loss was found to lead to embryonic lethality, and addi-
tional investigations in a hypomorphic allelic series of mice with
sequentially lowerPtenexpression revealed thatevensmall reduc-
tions in Pten doses can elicit cancer phenotypes (Alimonti et al.,
2010; Trotman et al., 2003). Conversely, systemic elevation of
Pten through transgenic overexpression results in a constitutively
augmented tumor-suppressive state (Garcia-Cao et al., 2012).
PTEN functions as a dual-specificity protein phosphatase
(DSP) with predominant enzymatic activity on phosphoinositides
(Maehama and Dixon, 1998). As a phospholipid phosphatase,
PTEN catalyzes the hydrolysis of the second messenger PtdIns
(3,4,5)P3 (PIP3) and counteracts the activation of the PI3K/AKT
pathway, thus regulating cellular growth, proliferation, andmeta-
bolism (Maehama and Dixon, 1998).
In line with its protein phosphatase function, PTEN has been
shown to dephosphorylate phosphopeptides in vitro (MyersCell 157, 595–610, April 24, 2014 ª2014 Elsevier Inc. 595
et al., 1998), and reported phosphoprotein targets include the
focal adhesion kinase, c-SRC, as well as PTEN itself (Tamura
et al., 1999; Tibarewal et al., 2012; Zhang et al., 2011).
Heterozygous deletion of Pten in mice faithfully phenocopies
biological features found in many human tumors with partial
loss of PTEN (Di Cristofano et al., 1998). However, reports indi-
cate that genetic loss of PTEN and mutations leading to PTEN
loss of function may not be equivalent. For instance, Marsh
et al. (1998) reported a genotype-phenotype correlation in
patients diagnosed with CD who developed several tumors,
including breast tumors. Importantly, they found that patients
harboring missense PTEN mutations in the phosphatase core
developed higher numbers of lesions than patients with trun-
cating mutations (Marsh et al., 1998). This led us to hypothesize
that expression of catalytically inactive mutant PTEN enzyme
may be more unfavorable than PTEN protein loss.
Regulation of PTEN function occurs through various posttrans-
lational modifications implicated in PTEN membrane recruit-
ment, subcellular localization, or protein-protein interactions
(Wang and Jiang, 2008). Structurally, PTEN belongs to the Class
I Cys-based protein tyrosine phosphatase (PTP) and, more spe-
cifically, to the VH1-like family (Alonso et al., 2004). PTEN con-
tains an N-terminal phosphatase domain with a conserved active
site; a C-terminal C2 domain followed by two PEST sequences
and a PDZ-binding domain (Lee et al., 1999). It has been reported
that PTEN interacts with a number of PDZ-domain bearing pro-
teins to achieve higher levels of complex formation (Sotelo
et al., 2012; Vazquez et al., 2001). We therefore hypothesized,
and have here demonstrated, that PTEN can interact with itself.
We show that dimer PTEN is active toward its phosphoinositide
substrate PIP3 and thereby inhibits the activation of the PI3K/
AKT signaling pathway. Critically, we find that in adimeric confor-
mation, cancer-associated missense mutations have dominant-
negative consequences over wild-type (WT) protein function,
with ensuing implications for tumorigenesis.
RESULTS
PTEN Exists in a Dimeric Complex
Given that VH1-like phosphatases are known to exist in higher
order complexes/dimers (Koksal andCingolani, 2011), we exam-
ined whether PTEN could form similar complexes. For this, we
performed coimmunoprecipitation (co-IP) experiments using
the PTEN null cell line PC3. By cotransfecting differentially
tagged PTEN variants we were able to reciprocally co-IP
GFPPTEN and MycPTEN (Figure 1A). Moreover, in 293T cells
overexpressing GFPPTEN, we were able to co-IP endogenous
PTEN (Figure 1B).
Monomeric PTEN has a molecular weight of 50–55 kDa in
denaturing conditions. If a dimeric PTEN existed, it would
migrate at double that size in nonreducing and nondenaturing
SDS-PAGE. Accordingly, immunoprecipitation (IP) and native
elution of MycPTEN from transfected PC3 cells revealed the
presence of two bands consistent with the monomeric and
dimeric status of the protein (100 kDa circa) (Figure S1A available
online). To control for overexpression artifacts, we repeated this
assay by pulling down endogenous Pten in NIH 3T3 and
confirmed the presence of two bands (Figure 1C).596 Cell 157, 595–610, April 24, 2014 ª2014 Elsevier Inc.Next, we investigated the contribution of covalent and nonco-
valent interactions to dimer formation and found that disulfide
bonds are not a major requirement for the stabilization of this
interaction (Figure S1B). We also verified PTEN homodimeriza-
tion in vitro by coexpressing GST-PTEN and His-PTEN in bacte-
ria. In these experiments, we successfully recovered His-PTEN
in GST-PTEN pull-downs (Figure 1D).
To further validate the direct binding between PTENmolecules
in a eukaryotic system, we employed bioluminescence reso-
nance energy transfer (BRET). To this end, we used Renilla
luciferase-PTEN (PTENRluc) as energy donor and GFPPTEN as
energy acceptor (Figure 1E); coelenterazine was used as sub-
strate for the luciferase. Coexpression of PTENRluc with
GFPPTEN generated a significant increase in the total BRET sig-
nal compared to empty GFP, with GFP emission only occurring
when in close proximity (<100 A˚) to the luminescent PTENRluc
(Figure 1F). We also performed competition assays. Coexpres-
sion of donor and acceptor proteins with increasing doses of
untagged PTEN showed a reduction of net BRET, providing
further evidence of direct PTEN-PTEN interaction (Figure 1G).
Finally, we sought to determine whether PTEN dimerization
occurs in both the nucleus and cytoplasm. Utilizing BRET, we
found no variations in nuclear emission over the total BRET
signal, neither in basal conditions nor upon serum stimulation,
suggesting that PTEN dimer likely exists in both compartments
(Figure 1H). This finding was confirmed in co-IPs performed
upon nuclear versus cytoplasmic fractionation (Figures S1C
and S1D). Thus, we have demonstrated by multiple approaches
that PTEN can exist in a homodimeric complex.
PTEN Dimer Is Catalytically Active
To identify the protein domains responsible for PTEN dimer for-
mation, we generated GST-fusion proteins with PTEN N termi-
nus (GST-PTENDC terminus) and PTEN C terminus domains
(GST-PTENDN terminus) (Figure 2A). Coexpression of GST-
PTEN full length (FL) with His-PTENFL confirmed the interaction
between the two FL proteins (Figure 2B). Notably, His-PTENFL
was pulled down by both GST-PTEN-domains in bacteria (Fig-
ure 2B). We then tested the binding by co-IPs in PC3 cells and
confirmed that in eukaryotic cells PTEN uses multiple interfaces
along the entire protein to achieve a dimeric conformation (Fig-
ures S2A and S2B).
To corroborate these findings, we tested the ability of different
PTEN domains to homodimerize in vivo (Figure 2C). In nonre-
ducing SDS-PAGE, total lysates from PC3 cells transfected
withMycPTENFL, MycPTENDN terminus, or MycPTENDPDZ re-
vealed the appearance of upper bands at twice the size of the
respective monomeric proteins. Strikingly, upon stabilization of
MycPTENDC terminus andMycPTENDCTDwith the protease in-
hibitor MG132, we observed dimeric bands with all PTEN vari-
ants tested (Figure 2D), with the MycPTENDC terminus showing
the highest propensity to self-associate (Figure 2E). Notably, the
MycPTENDC terminus and MycPTENDN terminus exhibited a
potential to oligomerize, as evidenced by additional higher
molecular weight bands (Figure 2D, asterisks).
We also studied binding directionality and found that while in
a closed head-to-tail monomeric conformation PTEN is inac-
tive toward its lipid substrate (Leslie and Foti, 2011), through
Figure 1. PTEN Exists in a Dimeric Complex
(A) Co-IPs from total lysate of PC3 cells. IP of
MycPTEN (top) and IP of GFPPTEN (bottom) with
specific tag antibodies revealed reciprocal PTEN-
PTEN interaction.
(B)Co-IPs fromtotal lysateof293Tcells, transfected
with GFPPTENWT and IP with anti-GFP antibody.
Western blot was probed with a PTEN antibody.
(C) NIH 3T3 cell lysates were IP with anti-rabbit
PTEN antibody; native elution and western blots
show monomer and dimer of the protein using
mouse anti-PTEN antibody.
(D) In bacteria, GST-PTEN specifically pulls down
His-PTEN.
(E) Renilla and GFP emissions are detected at
the indicated wavelengths. Administration of
Coelenterazine induces Renilla excitation that
generates BRET signal when in proximity to the
GFP. Bottom: images of fluorescent signals
generated by the different chimeras.
(F) Detection of PTEN-PTEN interaction by BRET
in PC3 cells transfected with the indicated plas-
mids. Bottom shows expression levels of the
different chimeras. Mean values with associated
SD are shown.
(G) Competition assays performed by BRET.
Bottom: expression levels of the indicated chi-
meras. Quantification of Un-tagged PTEN cloned
in the pcDNA3.1 vector is normalized to b-actin.
Mean values with associated SD are shown.
(H) In PC3, BRET signal is collected in a single cell
fashion and nuclear emission normalized over
average of total emission. Mean values with rela-
tive SD are shown.
See also Figure S1.head-to-head intermolecular binding, it achieves a more active
enzymatic conformation (Figures S2C–S2F).
We next tested the catalytic activity of antibody-purified
PTEN dimers from PC3 cells. PTENFL displayed different affin-
ities toward PTEN deletion mutant versions (Figure S2B), and
higher levels of dimerization between PTENFL and PTEN
domains correlated with higher levels of free phosphate release
(Figure S2E).
We likewise performed gel filtration of various PTEN species
followed by phosphatase assays using PIP3 as substrate. Total
lysates of HEK293 cells with exogenous MycPTEN expression
were fractioned and a low molecular weight range (30–
160 kDa) identified by western blot analysis (Figures 2F, top,
and S2G). Importantly, eluted fractions corresponding to dimeric
PTEN (fractions 26–27) generated higher phosphate release than
fractions of a lower molecular weight which contained mono-
meric PTEN (fractions 28–29) (Figure 2G). Thus, we concludeCell 157, 595–6that PTEN dimerization defines a more
active complex with respect to the less
active PTEN monomer.
Phosphorylation of the PTEN Tail
Regulates PTEN Dimerization
Next, we studied the conformational sta-
tus of PTEN by gel filtration analyses.FLAG-tagged PTEN without the C-terminal tail (FlagPTENDCTD)
was expressed in HEK293 cells and total lysates were frac-
tioned. Western blot analysis revealed a striking upward shift
of tail-less PTEN compared to PTENFL, indicating an enriched
dimeric status (Figure 2F).
Because the physiologic role of the PTEN tail is mediated by its
phosphorylation status (Vazquez et al., 2000), we performed gel
filtration analyses by using phosphomimetic and phosphodead
mutant-tail versions of PTEN. We focused specifically on amino
acids S380, T382, T383, and S385. By expressing nonphosphor-
ylatable PTEN (PTEN S380A, T382A, T383A, S385A: PTEN4A)
we functionally mimicked deletion of the PTEN C-terminal tail.
Notably, the PTEN4A presented the same upward shift we found
with expression of PTENDCTD (Figure 2F). In contrast, expres-
sion of a phosphomimetic PTEN (PTEN4E) prevented this shift,
indicating a possible role for PTEN tail-phosphorylation in
governing its dimeric status (Figure 2F).10, April 24, 2014 ª2014 Elsevier Inc. 597
Figure 2. Dimerization Defines a Pool of Catalytically Active PTEN
(A) Diagram of recombinant proteins showing PTEN FL and deletion mutants. In red, N terminus domain, amino acid (aa) 1–185; in orange, C terminus domain,
aa 186–403.
(B) GST-PTENFL and domains were purified (Ponceau-S staining); His-PTEN pulled down is detected by western blot.
(C) Schematic representing series of Myc-tagged PTENFL and deletion mutant vectors. Predicted molecular weights are indicated.
(D) PC3 cells were transfected with the indicated expression vectors. Total lysates were resolved by nonreducing SDS-PAGE and probed with an anti-Myc
antibody. Circles and squares indicate monomeric and dimeric PTEN conformations, respectively. Asterisks indicate oligomers of PTEN domains.
(E) Ratio between PTEN dimer/monomer in PTEN FL and deletion mutant series. Average of three independent experiments is shown with associated SD.
(F) Lysates from HEK293 cells transfected with the indicated PTEN vectors were separated by gel filtration. Fractions were resolved by SDS-PAGE and probed
with specific tag antibodies.
(legend continued on next page)
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Next, we assessed the phosphorylation level of PTEN dimer.
To this end, we immunopurified PTEN and eluted the complex
in nonreducing conditions. After tandem-column gel filtrations
we analyzed the immunocomplex by reducing and nonreducing
SDS-PAGE (Figure 2H). In reducing SDS-PAGE, immunopurified
PTENFL appeared in two peaks corresponding to a ‘‘low-’’ and a
‘‘high-molecular-weight complex’’ (Figure S2H). We then tested
the phospho/nonphospho status of the dimeric PTEN in nonre-
ducing SDS-PAGE. First, with a total PTEN antibody we con-
firmed the presence of PTEN as amonomer and dimer (Figure 2I,
right). Importantly, we found that while a specific ‘‘phospho-
PTEN’’ antibody only recognizes the monomeric form, the rela-
tive ‘‘nonphospho’’ PTEN showed the appearance of both
monomeric and dimeric protein (Figure 2I, left and middle).
Finally, we tested total lysates from HEK293 cells expressing
PTEN4A and PTEN4E. Here, we found that while PTEN4E only
runs as a single monomeric band (Figure 2J, bottom), PTEN4A
showedmonomeric and dimeric PTEN conformations (Figure 2J,
top), in agreement with the shift found by gel filtration. Thus we
demonstrate that phosphorylation of the C-terminal tail main-
tains PTEN as a monomer, whereas the absence of phosphory-
lation is associated with a dimeric conformation.
PTEN Cancer-Associated Mutations Exert Dominant-
Negative Effects over Wild-Type Protein
We then asked if mutant PTEN protein could form dimers and
whether mutations altered dimer formation or activity. The
most studied cancer-associated PTEN mutations are the Cys-
124 to Ser (C124S) and the Gly-129 to Glu (G129E). C124S
mutation generates a catalytically dead PTEN variant that is
associated with endometrial cancer and is reported to com-
pletely ablate PTEN phosphatase activity (Bonneau and Longy,
2000; Myers et al., 1997), whereas the G129E mutation is asso-
ciated with CD and abrogates the phosphoinositide phospha-
tase function but retains activity toward phosphopeptides
(Liaw et al., 1997; Myers et al., 1998). Both mutations lie in the
PTEN catalytic core.
To test our hypothesis, we first analyzed the ability of
MycPTENC124S and MycPTENG129E to homodimerize. In
nonreducing conditions, we found that both mutants appear as
monomers and dimers, like the wild-type protein (Figure 3A).
PTEN mutants were also able to form heterodimers with wild-
type PTEN as found in our co-IP experiments (Figure 3B).
BRET experiments further demonstrated that PTENWT-Rluc in-
teracted with either GFPPTEN-C124S or G129E (Figure 3C).
In bacteria, GST pull-down experiments confirmed that His-
PTENWT binds both GST-tagged PTEN mutants (Figure 3D).
Importantly, purified heterodimers were tested for phosphatase
activity on PIP3. In control experiments, GST-PTENWT alone or(G) Fractions containing different conformations of PTEN and collected as in (F) we
values from triplicate wells with associated SD are shown.
(H) Experimental flow chart: cell lysates were subjected to IP with an anti-Myc an
tandem-column gel filtration. See also Figure S2H. Collected fractions were reso
(I) Fractions collected as in (H) were resolved by nonreducing SDS-PAGE and pr
(J) Nonreducing SDS-PAGE of eluted fractions generated as in (F) were blotted w
FlagPTEN4E probably due to posttranslational modifications.
See also Figure S2.a His-PTENWT:GST-PTENWT mix produced effective free
phosphate release. However, heterodimers comprised of His-
PTENWT:GSTPTENC124S or His-PTENWT:GSTPTENG129E
had reduced capacity to hydrolyze PIP3 compared to GST-
PTENWT (Figure 3E), leading us to consider the possibility that
in a heterodimeric state, the catalytically inactive mutations in-
hibited activity of the wild-type PTEN protein toward PIP3, as
we next demonstrated in vivo.
Generation and Characterization of Pten Knockin
Mutant Mice
To investigate the physiological consequences of PTEN-PTEN
mutant heterodimers, we generated mouse models expressing
PTENC124S and PTENG129E (Figures S3A and S3B). For the
PtenC124S/+ and PtenG129E/+ mouse models, we substituted T
to A at position 370 or G to A in position 386 of Pten exon5,
respectively (Figure 3F).
In performing the in vivo characterization of these new Pten KI
mice, we also aimed to investigate two critical aspects of PTEN
regulation: stability and localization. First, since many PTEN
missense point mutations render PTEN unstable (Georgescu
et al., 1999), we measured the mutant Pten proteins levels in
our Pten KI mice. We observed that PtenC124S/+ and PtenG129E/+
express a total level of Pten that is comparable to levels in Pten
wild-type mice (Figure 3G). Second, to exclude the contribution
of defective cellular distribution to our analysis, we performed
cell-fractionation and immunofluorescence (IF) analyses. Here,
we found that PtenC124S/+ and PtenG129E/+ MEFs (Figures 3H–
3J) displayed comparable Pten localization patterns to wild-
type cells.
In Vivo Confirmation of the Dominant-Negative
Functions of Mutant Pten
Because homozygous Pten loss is lethal in embryogenesis, we
investigated the possibility of generating homozygous Pten KI
mice. Three independent crosses per mutation failed to yield
live pups with a homozygous mutant genotype, indicating that
the lipid phosphatase activity of Pten is an essential function dur-
ing embryogenesis (Figures S4A and S4B).
To evaluate the consequences of harboring loss-of-function
Pten mutants in heterozygosity, we established cohorts of
PtenC124S/+, PtenG129E/+, and Pten+/mice as controls. Because
Pten heterozygosity initiates neoplastic transformation of epithe-
lial tissues and leads to severe lymphoproliferation (Di Cristofano
et al., 1999), we collected a number of organ samples for
histological analysis. We found that young mice between 8
and 16 weeks of age showed hyperplastic changes in the
lymph nodes, with expansion of T cells (data not shown). Surpris-
ingly, unlike Pten+/ mice, a significant number of PtenC124S/+,re tested for their activity toward PIP3 and normalized over protein levels. Mean
tibody. Immunocomplexes were eluted in native conditions and separated by
lved by reducing (Figure S2H) and nonreducing SDS-PAGE (I).
obed with the indicated PTEN antibodies.
ith anti-Myc (top) and anti-Flag (bottom) antibodies. Asterisk indicates a shift in
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Figure 3. PTENC124S and PTENG129E Mutations Heterodimerize with PTEN Wild-Type and Inhibit Its Phosphatase Function
(A) Nonreducing SDS-PAGE of lysates from PC3 cells transfected with MycPTENWT or mutant vectors and IP with an anti-Myc antibody.
(B) IPs from PC3 cell lysates transfected with the indicated vectors were performed and western blots probed with an anti-PTEN antibody.
(C) BRET analysis on PC3 cells complemented with the indicated vectors. Mean values with associated SD are shown.
(D) GST-pull down (in Ponceau-S staining) reveals binding between prokaryotic PTENWT and mutant versions. Western blots are probed with anti-His antibody.
(legend continued on next page)
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PtenG129E/+ mice developed lymphoproliferation features by
16 weeks (Figure S3E). Accordingly, older Pten KI mice had
increased spleen weights, compared to Pten+/ mice, owing to
severe extramedullary hematopoiesis and lymphoid hyperplasia;
we also found extended expansion of white blood cells in the
peripheral blood (Figure S3F). In solid tissues, the tumor spec-
trum of Pten KI mice was indistinguishable from Pten+/ mice,
with lesions developing in several glands and organs (Figures
S3C and S3D). However, histological assessments at different
time points revealed that a greater proportion of Pten KI mice
developed adenomas of the thyroid, adrenal, and gallbladder,
with 2 out of 29 PtenC124S/+, and 3 out of 37 PtenG129E/+ male
mice also developing invasive adenocarcinoma of the thyroid.
In addition, three PtenC124S/+ mice developed lung adenomas,
and 4 out of 30 PtenG129E/+ female mice developed liver ade-
nomas, a lesion never observed in our Pten+/ mice (Figures
S3C and S3D). In mammary tissues, 68.9% of our Pten+/
mice between 9 and 12 months developed hyperplastic lesions
(13 out of 29, 44.8%) or small adenocarcinomas (7 out of 29,
24.1%). Lesions developed in 66% and 67% of PtenC124S/+and
PtenG129E/+ mice, respectively; however, along with a number
of hyperplasia cases and small adenocarcinomas (9 out of 27,
33.3%, for PtenC124S/+, and 7 out of 24, 29.1%, for PtenG129E/+)
we also found that 33.3% of PtenC124S/+ mice (9 out of 27) and
37.5% of PtenG129E/+mice (9 out of 24) developed large invasive
adenocarcinomas (Figures 4A and 4B). Thoracic and inguinal fat
pads presented massive expansion of epithelial cells and con-
nective tissue, with central necrotic areas likely due to tumor
size, which reached 0.6 cm2 on average (Figures 4C and S4C).
As PTEN loss also leads to defects in neuronal development,
we assessed the status of different neuronal populations (Fraser
et al., 2004). Histopathological analysis revealed that only the
pituitary gland presented signs of tumorigenesis, with adenomas
developing primarily in the anterior lobe (Figure S4E) (Bai et al.,
2006). However, in the cerebellum, we found that while Pten+/
mice had histologically normal brains, both Pten KI cohorts
developed features of Lhermitte-Duclos disease, or ‘‘dysplastic
gangliocytoma’’ (Figures 4D, 4E, S4D, and S4G) (Backman
et al., 2001; Kwon et al., 2001). An average of 25% of
PtenC124S/+ and PtenG129E/+ mice had enlarged areas in the cer-
ebellum, with disorganized spreading of granule cells into the
molecular layer, increased thickness of the molecular layer itself,
and the presence of neurons expressing the neuronal marker,
NeuN (Figure 4F). Immunostaining confirmed the expansion of
glial cells (mostly astrocytes, GFAP positive, Figure 4F), together(E) Fractions of PTEN dimers purified as in (D), plus GST-PTENWT alone were pur
PIP3 as substrate. PO4 released is normalized over levels of His-PTEN pulled do
values of triplicate wells with associated SD are shown.
(F) Sequencing of Pten-exon5 amplified fromDNA of targeted ES cells. Electrophe
T-to-A; bottom: G129E, G-to-A).
(G) Analysis of Pten protein levels. Total lysates of MEFs and adult tissues (lung an
resolved by SDS-PAGE. Pten quantification is normalized to b-actin and relative
(H) Nuclear versus cytoplasmic fractionation of MEFs. Comparable distribution o
(I) Pten IF in MEFs: 120 cells per field (2003 magnification) were scored on avera
membrane and in the cytosol) is shown with associated SD.
(J) Representative IF showing endogenous nuclear (white arrowheads) and
represent 50 mm.
See also Figure S3.with an increased number and size of glial fibers, as shown by
positivity to the proliferation marker PCNA (Figure S4F). Affected
areas reshaped the structure of the cerebellar lobes and led to
dispersion of the Purkinje cells in the molecular layer (Calbindin
staining in Figure 4F). These ‘‘PHTS’’ features were found as
early as 4 months of age and presented in small localized areas,
as well as in more developed lesions that pervaded the whole
cerebellum (Figure 4E). Notably, conditional loss of Pten in the
brain, under Gfap-driven Cre expression, leads to similar find-
ings (Backman et al., 2001; Kwon et al., 2001). Taken together,
our in vivo data reveal that Pten KI mice have an exacerbated
tumor spectrum and PHTS features compared to Pten+/ mice.
Pten KI Mice Show Higher Sensitivity to Growth Factor
Stimulation and Increased Akt Activation
To investigate the molecular basis of the augmented tumorigen-
esis observed in Pten KIs versus Pten+/ mice, we monitored
downstream effectors of Pten. For this, we isolated primary
mammary epithelial cells (MECs) from young Pten+/+, Pten+/,
PtenC124S/+, and PtenG129E/+ female mice to examine levels of
Akt phosphorylation. Importantly, while Pten+/ derived MECs
had increased phospho-Akt levels compared to wild-type cells,
lysates from PtenC124S/+ and PtenG129E/+ derived MECs dis-
played levels of Akt activation consistently higher than those
found in Pten+/ (Figures 5A and 5B). We next examined Akt
phosphorylation in preonset mammary glands of 10- to 12-
week-old mice by immunohistochemical staining (IHC) and
found that Pten KI mice presented the strongest signal (Fig-
ure 5C), which persisted in tumor lesions of older mice (Figures
S3G and S4C).
To further test the propensity of Pten mutations to induce Akt
hyperactivation, we generated mouse embryonic fibroblasts
(MEFs). Insulin-like growth factor (IGF) stimulation led to acute
Akt phosphorylation in Pten-KI-derived MEFs, again much
higher than in Pten+/ cells (Figure 5D). Similar results were
observed upon insulin stimulation (Figure S5A). In addition, by
monitoring the activation profile over time, we found that after
1 hr of insulin stimulation, Pten KI MEFs sustained higher levels
of phospho-Akt (Figure 5E).
We next examined cellular levels of PIP3, which is mainly
found on the leading edges of filopodia and lamellipodia, to stim-
ulate cell migration and invasion (Ko¨lsch et al., 2008). In MEFs, IF
experiments showed that 1 min of insulin stimulation led to PIP3
accumulation at themembrane of all samples, with PtenKIMEFs
showing the strongest signal (Figure 5F).ified. Catalytic activity of PTEN dimers was tested in phosphatase assays using
wn and is shown relative to the PO4 released by GST-PTENWT alone. Mean
rograms show expression of both Ptenwt and Ptenmutated alleles (top:C124S,
d spleen) derived from Pten+/+, Pten+/, PtenC124S/+, and PtenG129E/+micewere
to WT band.
f Pten was observed across the different genotypes.
ge. Percentage of Pten accumulation in the nucleus versus cytoplasm (at the
cytoplasmic (red arrowheads) distribution of Pten in MEFs. Scale bars
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Figure 4. Dominant-Negative Effect of PTEN Cancer-Associated Mutations Leads to Enhanced Tumorigenesis and Development of
Hamartoma Features
(A) Pie charts showing breast tumor distribution in Pten+/, PtenC124S/+, and PtenG129E/+ female mice between 9 and 12 months of age.
(B) H&E staining of tumoral lesions found in breast tissues of Ptenmouse lines. Top: arrows point to hyperplasia (left) and small adenocarcinomas (right) found in
the 68.9% of Pten+/mice (n = 20 out of 29); LN, lymph nodes. See also Figures S3E and S3F. Bottom: sections of large breast adenocarcinomas developing in
34% of PtenC124S/+mice (n = 9 out of 27), left, and 37.5% of PtenG129E/+mice (n = 9 out of 24), right. Asterisks indicate areas of epithelial expansion surrounded by
connective tissue. Arrows point to areas of necrotic tissue found in the middle core of the tumors. Scale bar represents 1 mm in hyperplasia sample, top left; and
500 mm in the remaining panels.
(C) Tumor area of large breast adenocarcinomas found in Pten KI mice. Inset: picture of large breast tumor (red arrowhead) developing in the inguinal fat-pad of a
9-month-old PtenC124S/+ female mouse. Histogram shows average tumor area measured on paraffin blocks samples (side 3 side). Br, breast; LN, lymph node.
Mean values with associated SD are shown.
(D) Lhermitte-Duclos disease develops in the cerebellum of Pten KI mice. Table shows penetrance of disease in PtenC124S/+ (six females and one male) and
PtenG129E/+ mice (three females and seven males). See also Figures S4D and S4G.
(legend continued on next page)
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Next, wemonitored activation levels of Akt isoforms. Out of the
three, Akt1 and Akt2 are more widely expressed, and their con-
tributions to tumorigenesis have been better characterized (Gon-
zalez and McGraw, 2009). Thus, we performed IP-western blot
analysis on Akt1 and Akt2 and found that both proteins were hy-
perphosphorylated in Pten KI MEFs (Figures S5C and S5D). We
also examined expression levels of key components of the PI3K
pathway and found no changes in total levels of its upstream or
downstream components (Figure 5G); nor did we find alteration
in the formation of the PI3K complex (p85:p110 binding) across
the Pten genotypes (Figure S5B).
We then monitored the activation of several Akt targets, in-
cluding the mTORC1 complex. We found that upon insulin stim-
ulation, Pten KI MEFs displayed increased levels of PRAS40
phosphorylation compared to Pten+/ cells, resulting inmTORC1
activation and faster accumulation of phospho-S6, its down-
stream substrate (Figures 5H, S5F, and S5G). Pten KI MEFs
also displayed reduced levels of IRS1, probably due to negative
feedback loops driven by mTORC1activation (Figure 5G) (Shah
et al., 2004).Wealsomonitored activation of Akt targets including
TSC2, Foxo1, and Foxo3a, but while both Foxo proteins were
more phosphorylated in Pten KI MEFs compared to Pten+/,
the status of phospho TSC2 remained unchanged (Figure 5H).
Finally, we tested the status of proposed Pten protein sub-
strates and established their potential contribution to Pten loss
driven tumorigenesis. (Tamura et al., 1999; Zhang et al., 2011).
In our experimental conditions, however, while IGF stimulation
led to Akt hyperactivation, the phosphorylation status of Fak
and Src were not significantly affected across the Pten geno-
types (Figure S5E).
Dimerization and Membrane Recruitment Identify an
Active Pool of PTEN In Vivo that Is Out-Competed by
Mutant PTEN
We then immunopurified Pten fromPten+/+, Pten+/,PtenC124S/+,
and PtenG129E/+ MEFs and tested the respective phosphatase
activity toward PIP3. We found that free phosphate production
by the heterodimeric complexes was lower than that found
under Pten heterozygous conditions. Accordingly, reduced
PIP3 hydrolysis led to increased Akt phosphorylation (Figures
6A and 6B).
Because PIP3 is produced in the inner leaflet of the plasma
membrane, we next analyzed Pten membrane recruitment. To
this end, we coexpressed GFPPTEN WT or mutants alongside
untagged PTENWT in PC3 cells and monitored the ability of
the different GFPPTEN species to localize to the plasma-mem-
brane (PM) (Figure S6A). We found that, upon starvation and
serum stimulation, GFPPTEN mutant proteins showed a 12%
greater concentration (on average) at the membrane than
GFPPTEN WT (Figure S6B).(E) H&E staining of cerebellar sections from Pten mouse lines. Top: histologically
(ML), internal granule cell layer (IGL), and deep cerebellar nuclei (DCN). Bottom: L
(left) or developing through the entire cerebellum (right). See also Figure S4D. Sc
(F) Immunohistochemistry (IHC) of cerebellar sections from 10-month-old Pten
spreading into the ML. Calbindin immunostaining shows dispersion of Purkinje c
staining identifies presence of scattered neurons. Scale bars represent 25 mm.
See also Figure S4.To verify that PTEN is present at the membrane as homo-
or heterodimers, we repeated this assay by coexpressing
GFPPTEN variants with mCherry-tagged PTENWT. Coexpres-
sion of mCherryPTENWT with GFPPTENWT displayed a linear
accumulation of GFP and mCherry signals at the PM, with
<2% intrinsic variation, likely due to different backbone plas-
mids. However, in coexpressing C124S or G129E-GFP variants
with mCherry-PTENWT, we observed that the GFP detection at
the PM was only 4% more intense than the mCherry signal (Fig-
ures 6C and S6C), suggesting that, although both mutants are
recruited to the membrane more rapidly than PTEN WT, they
are also able to promote enhanced mCherry-PTENWT mem-
brane recruitment through dimerization.
In addition, co-IPs from PC3 cell-membrane fractions con-
firmed that MycPTENWT can bind GFPPTENWT and GFPPTEN
mutants at the membrane (Figure 6D). Thus we propose that
‘‘inactive’’ hetero- and homodimers may displace and out-
compete the function of ‘‘active’’ PTEN WT homodimers.
Consequence of PTEN Mutations on Loss of
Heterozygosity and Akt Activation in Mouse Models and
Humans
In the mouse, monoallelic loss of Pten leads to tumor initiation
while cancer progression often selects for loss of the functional
Pten allele (Hollander et al., 2011). Thus, we asked whether in
Pten KI mice, the dominant-negative action of mutant over
wild-type Pten protein would trigger advanced tumorigenesis
also in the absence of loss of heterozygosity (LOH). We there-
fore performed Southern blot (SB) analysis and laser capture
microdissection (LCM) on large breast adenocarcinoma sam-
ples from Pten KI mice. By SB we found that on average,
50% of the Pten KI breast samples fully retained the Pten wt
allele (Figure S6D). To test a larger number of samples, we
then performed LCM and PCR amplification on DNA extracts
and found mixed genomic profiles with only one out of six
PtenC124S/+ samples (16%) displaying total LOH and two out
of six PtenG129E/+ samples (33%) presenting either partial or
total LOH (Figure 6E).
Next, we examined the status of the Pten protein by IHC and
found predominantly positive staining, with areas of reduced in-
tensity in agreement with the percentage of LOH found by SB
and LCM (Figure 6F). This finding argues that the dominant-
negative effect of Pten mutations exerts their negative protu-
morigenic effects even in the absence of LOH; however, when
cancer arises, intratumoral variability and accumulation of addi-
tional mutations will eventually favor focal loss of Pten. Thus the
persistent Akt hyperactivation, as found in large adenocarci-
nomas (Figure S6E), leads to accelerated cancer formation,
while PTEN LOH, when observed, may further favor tumor
progression.normal cerebellum from Pten+/+ and Pten+/ mice displaying molecular layer
hermitte-Duclos disease in Pten KI mice present in small areas of early lesions
ale bar represents 1 mm.
mouse lines. From the top: H&E staining shows disorganized granule cells
ells due to granule cells overgrowth (GFAP immunostaining). NeuN immuno-
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Figure 5. PtenC124S/+- and PtenG129E/+-Associated Tumorigenesis Is Driven by Akt Hyperactivation
(A) Total lysates of mammary epithelial cells (MECs) derived from 10- to 12-week-old female mouse lines. MECs were starved overnight and stimulated for 10min
with full serum (see Experimental Procedures).
(B) Phospho-Akt levels are normalized over total protein levels. Average of three independent experiments is shown.
(C) IHC of Phospho-Akt (S473) in breast tissue of 12-week-old female mice (top) and 9-month-old female mice (bottom). Scale bars represent 50 mm.
(D) Activation of PI3K pathway in MEFs. Total lysates were resolved by SDS-PAGE and probed with the indicated antibodies. Phospho-Akt levels are normalized
over total Akt.
(E) MEFs were starved for 3 hr and stimulated with 0.5 mg/ml of insulin for the indicated time points. Phospho-Akt levels are normalized over total Akt.
(F) PIP3 immunostaining inMEFs.MEFswere starved for 3 hr, stimulated with 0.5 mg/ml of insulin for 1min, and fixedwith 4%PFA (see Experimental Procedures).
Arrows point to accumulation of PIP3 at the leading edges of membrane projections. Scale bars represent 50 mM.
(G) Total lysates of MEFs were resolved by SDS-PAGE and probed to detect protein levels of members of the PI3K/Akt pathway.
(H) Activation of Akt targets in Pten-derived MEFs. MEFs were starved for 3 hr and stimulated for the indicated time points. Total lysates were resolved by SDS-
PAGE and probed with the indicated antibodies.
See also Figure S5.
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Figure 6. Akt Hyperactivation Leads to Faster Tumor Formation
(A) Analysis of Pten catalytic activity. Total lysates of MEFs were IP with an anti-Pten antibody, immunocomplexes eluted in native conditions, and relative
phosphatase activity normalized over levels of Pten IP. Mean values from triplicate wells with associated SD are shown.
(B) Levels of Akt phosphorylation found in MEFs treated as in (A).
(C) PC3 cells were transfected with mCherry-PTENWT alongside GFP-PTENWT or mutants. Translocation to PM was assayed through generation of ratiometric
images. Average ratios were calculated based on fluorescent intensities of mCherry and GFP species at the PM versus intensities found in the cytosol during
serum reactivation. Quantification of PTEN distribution is shown.
(D) Co-IPs from membrane or cytosolic fractions of PC3 cells transfected with the indicated PTEN vectors. PanCadherin and LDH are membrane and cytosolic
protein markers, respectively
(E) Laser capture microdissection (LCM) analysis performed on large breast adenocarcinoma samples of Pten KI mice. Top: representative PCRs of Pten exon5
locus showing levels of wild-type and targeted Pten alleles found in microdissected breast samples. Bottom: percentage of LOH in breast tumor samples, n = 6
per genotype.
(F) IHC of large breast adenocarcinomas from 10-month-old Pten KI female mice. Pten expression ismaintained in the majority of the breast tumor with exception
of localized areas with reduced intensity (surrounded in white). LOH, area with loss of heterozygosity.
(G) Association study between PTEN status and AKT phosphorylation in human cancer (see Experimental Procedures). Samples harboring PTEN mutation are
associated with higher levels of phospho-AKT(T308) (top) and phospho-AKT(S473) (bottom) compared to samples with PTEN heterozygosity.
(legend continued on next page)
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To assess whether our observations were consistent with the
molecular changes occurring in human tumorigenesis, we
examined the association between PTEN mutational status
and AKT activation in human cancers. For this, we analyzed
data sets from The Cancer Genome Atlas available at the cBio
portal (http://www.cbioportal.org) and matched the genetic
status of PTEN with the reverse-phase protein arrays (RPPA)
data for AKT. We found that samples with heterozygous muta-
tions in PTEN (and no copy number alteration, including two
PTENG129E mutant cases) were associated with higher levels
of AKT phosphorylation (on both Thr308 and Ser473) compared
to samples with heterozygous PTEN loss (and no additional mu-
tations) (Figure 6G), independent of total Akt levels (Figure S6F).
These data support the notion that PTENmutations have greater
consequence than heterozygous PTEN loss in promoting PI-3K/
AKT hyperactivation andmay predict for higher sensitivity to AKT
inhibition in human cancers.
Genetic Assessment of the Dominant-Negative Role of
Mutant Pten
Finally, we reasoned that, if our model was correct, then the
observed differential signaling output between Pten KI cells
versus Pten+/ should be absent in PtenKI/ versus Pten/ cells.
Unfortunately, this could not be addressed in MEFs because
complete Pten loss is known to trigger cellular senescence in
these cells (Chen et al., 2005); indeed, we found that
PtenC124S/+MEFs presented increased senescence overPten+/
MEFs upon passaging (Figures S6G–S6I). To overcome this
problem, we made use of a conditional knockout strategy
induced by the CD4-Cre recombinase, which is active in the
double-positive lymphocyte stage of thymus development (Fig-
ure 6H). Extracted thymocytes were cultured and their PI3K-
signaling output analyzed by western blot and flow cytometry
analysis, respectively. Critically, in this setting we found no
consistent differences in signaling output across the genotypes
(Figures 6I and 6J), further supporting a model in which Pten
mutations enhance PI3K/Akt oncogenic signaling by inhibiting
its WT counterpart.
Functional Evaluation of PTENR130G Mutation
Because PTENC124S and PTENG129E mutations are only
found in a subset of cancer and genetic syndromes, we next
tested the functional role of three additional PTEN mutations
more commonly found in human disease: PTENR130G,
PTENR130X, and PTENR233X (Bonneau and Longy, 2000).
PTENR130X and R233X nonsense mutations introduce stop
codons that generate very unstable PTEN proteins that are
almost undetectable (Figure S7A) and thus are functionally com-
parable to the PTEN heterozygous condition. The PTENR130G
missense mutation, however, generates a stable protein that(H) Ptenfl/fl and PtenC124S/fl mice were crossed with CD4-driven Cre transgenic
thymocyte development. DN, double-negative thymocytes; SP, single-positive (r
(I) Thymocytes from 3- to 4-week-old mice with the indicated genotypes were ext
and probed with the indicated antibodies.
(J) Representative flow histogram of thymocyte populations stimulated with Ant
show comparable levels of phospho-Akt.
See also Figure S6.
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2000). In this respect, PTENR130G phenocopies PTENC124S
and PTENG129E, so we further investigated its potential domi-
nant-negative effect.
First, we confirmed that this mutation has no suppressive
effect on phospho-AKT levels in PTEN null cells (Figure 7A).
We next determined that PTENR130G can interact with WT
PTEN in bacteria as well as eukaryotic cells (Figures 7B and
7C). Then, by testing the phosphatase function of HisPTENWT-
GSTPTENR130G heterodimer purified from bacteria, we found
that when bound together, PTENR130G limits the function of
the WT protein to inhibit PIP3 dephosphorylation (Figure 7D). In
addition, overexpression of PTENmutations in PTEN-competent
293T cells displayed increased phospho-AKT on T308 than cells
expressing empty vector, overcoming the function of endoge-
nous PTEN (Figure 7E).
Finally, we found that samples harboring mutations on
PTENR130 either mutated to Gly (R130G) or to Gln (R130Q) in
a total of 19 samples from glioblastoma and endometrial cancers
exhibited higher levels of AKT phosphorylation than samples
with monoallelic loss of PTEN (Figure 7F).
DISCUSSION
In this study, we have demonstrated that PTEN dimerization is
critical for its lipid phosphatase function. We have also proposed
that dimeric PTEN complexes are more active than PTENmono-
mer in dephosphorylating PIP3 and regulating PI3K signaling. By
studying two PTEN cancer-associated mutations, we revealed
that while disrupting PTEN activity in cis, PTENC124S and
PTENG129E inhibit the WT protein function in trans in a domi-
nant-negative manner as a result of heterodimerization. In turn,
this reduced Pten lipid-phosphatase activity leads to Akt hyper-
activation and increased tumorigenesis in the mouse.
These findings allow us to reach several conclusions. Mecha-
nistically, we have defined that PTEN exists as a dimer. Given
that PTEN is part of the VH1-like family of DSPs, it is relevant
that the prototypical VH1 phosphatase is known to exist in a
dimeric-quaternary complex whose assembly is essential for
the recognition of its substrate, STAT1 (Koksal and Cingolani,
2011). Moreover, phosphorylation of the PTEN tail is known to
produce an inactive form of the enzyme in a closed conformation
(Leslie and Foti, 2011). In agreement, we provide evidence that
dephosphorylation of the PTEN-tail, while favoring a more
open conformation, also allows subsequent dimerization and,
possibly, oligomerization, in view of the multiple interfaces found
to mediate the PTEN-PTEN interaction.
The role of PTEN dimerization in cancer is particularly impor-
tant when we consider the high frequency of PTEN mutations
in sporadic tumors and inherited syndromes. In this study, wemice (left). Pten deletion specifically occurs at the double-positive (DP) stage of
ight).
racted and stimulated as indicated. Total lysates were resolved by SDS-PAGE
i-CD3/Anti-CD28 for the indicated time. Pten/ and PtenC124S/ thymocytes
Figure 7. PTENR130G Parallels PTENC124S and PTENG129E Mutations
(A) Total lysates of PC3 cells transfected with PTEN WT and mutant expression vectors. Western blots were probed with the indicated antibodies.
(B) Bacteria were cotransformed with His-PTENWT vector alongside empty GST, GST-PTENWT, or GST-PTENmutant vectors as indicated. Protein lysates were
subjected to GST pull down and SDS-PAGE blots probed with His-tag antibody.
(C) Co-IPs from total lysates of PC3 cells transfected with the indicated vectors and IP with a Myc-tag antibody. Western blot revealed interaction between
PTENWT and PTENR130G mutant protein.
(D) Phosphatase assay of PTEN dimers purified from bacteria. PO4 released is normalized over levels of His-PTEN pulled down and shown relative to the PO4
released by GST-PTENWT alone. Mean value of triplicate wells with associated SD are shown.
(E) HEK293T transfected with the indicated MycPTEN vectors were starved overnight and stimulated with 10% serum for 10 min. Total lysates were resolved by
western blot and probed with the indicated antibodies. Phospho-AKT levels are normalized over total AKT.
(F) Association study between AKT activation and PTEN mutations at aa R130 in human cancers.
(G) Top: Pten heterozygosity leads to Akt activation and tumorigenesis. Heterozygous expression of cancer-associated PTEN mutations leads to formation of
catalytically inactive heterodimers. Consequentially, increased PIP3 levels induce Akt hyperactivation and augmented tumorigenesis (bottom).
See also Figure S7.
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have analyzed in vivo and in vitro two cancer- and CD-associ-
ated missense mutations and extended our analysis to a third
mutation, PTENR130G. In the future, it will be important to study
various PTENmutations in a systematic manner. It is tempting to
speculate that other PTENmutants may affect the function of the
PTEN WT protein through physical interactions and perhaps at
multiple levels, e.g., by affecting PTEN extracellular export (Hop-
kins et al., 2013; Putz et al., 2012).
Clinically, our study implies that patients harboring these, or
similar loss-of-function missense mutations, may be more sus-
ceptible to malignant cancer and may develop it more rapidly
than patients expressing reduced levels of PTEN or expressing
PTEN-destabilizing mutations. Thus we propose that PTEN
mutational status may be utilized to stratify patients who may
benefit from earlier and more radical therapeutic intervention
modalities, potentially leading to improved prognoses.
Although we cannot exclude the possibility that certain PTEN
mutations may become competent toward targets not recog-
nized by the wild-type protein in a ‘‘gain-of-function’’ scenario
(Wang et al., 2010), our genetic analyses support a model in
which the ability of mutant PTEN to interfere with WT protein
function contributes to exacerbation of tumor spectrum
compared to Pten heterozygosity (Figure 7G). While these muta-
tions induce acceleration of tumorigenesis, they specifically act
by further lowering Pten activity rather than engaging alternative
pathways. Accordingly, we found that Pten KI mice developed
Lhermitte-Duclos disease, as previously reported in mice with
total conditional Pten loss, while lesions of different histological
origins not associated with Pten loss (such as sarcomas) were
not observed.
Additionally, in monitoring the activation status of proposed
PTEN phosphoprotein targets we found no obvious changes
upon IGF stimulation, or variation between tumor spectra of
the two Pten KI models. This implies that even if cancer-relevant
PTEN phosphoprotein targets are present and deregulated in
PtenC124S/+ mice, concomitant Akt hyperactivation may over-
come their effects, perhaps due to increased cellular senes-
cence (Figure S6G). While several reports have highlighted the
possibility that PTEN protein phosphatase activity may be
related to regulation of migration and invasion (Tibarewal et al.,
2012), in our in vivo analysis of the Pten KI mice we did not
observe metastasis. However, the general exacerbation of solid
tumorigenesis in multiple organs and pronounced lymphoprolif-
eration may have masked a possible metastatic phenotype in
elder mutants.
In summary, we have identified features of PTEN biology
through the characterization of cancer-associated PTEN
missense mutations. Given the ongoing development of agents
targeting the PI3K pathway including AKT-inhibitors, our findings
may help to identify patients that may be sensitive to these
agents due to high levels of AKT activation associated with a
PTEN mutant state.EXPERIMENTAL PROCEDURES
Western Blotting, Immunoprecipitation, and In Vitro Binding
For details on western blotting, immunoprecipitation, and in vitro binding
please refer to Extended Experimental Procedures.608 Cell 157, 595–610, April 24, 2014 ª2014 Elsevier Inc.Gel Filtration Chromatography
For gel filtration experiments please refer to Extended Experimental
Procedures.
Mice and Immunohistochemistry
Autopsy and histological analysis was performed on cohorts of female and
male mice from 2–13 months of age. Mouse tissues were fixed in 4% PFA.
Normal and tumor tissues were embedded in paraffin, sectioned, and hema-
toxylin and eosin (H&E) stained for pathological evaluation. Brain tissues
were fixed in Bouin’s solution. Please refer to Extended Experimental Proce-
dures for details on the generation of mouse lines. All mice were cared for
according to NIH-approved institutional animal care guidelines and studies
approved by the Institutional Committee at the Beth-Israel DeaconessMedical
Center.
Studies with Primary Cells
Mouse embryonic fibroblasts (MEFs) were isolated at day E13.5 and main-
tained in culture as described (Todaro and Green, 1963). MEFs between
passages 1 and 3were used for all experiments. Senescence assayswere per-
formed as described (Chen et al., 2005).
Isolation of primary mammary epithelial cells (MECs) was performed as pre-
viously described (Song et al., 2013). Please refer to Extended Experimental
Procedures for details.
PtdIns(3,4,5)P3 Phosphatase Assay
PC3 cells and primary MEFs lysates from Pten lines were IP and subjected to
native elution. For phosphatase assays, a solution with 25 mM Tris-HCl
(pH 7.5), 140 mMNaCl, 1 mM DTT, and 100 mMdiC8-PtdIns(3,4,5)P3 (Echelon)
was prepared and assay ran at 37C for 45 min. Free phosphate release was
measured with Green Reagent (Biomol) and according to the manufacturer’s
instructions.
Population BRET Imaging
PC3 cells seeded on 35 mm wells were transfected with indicated expression
vectors. After 48 hr, cells were scraped and transferred into a white OptiPlate-
96 (Perkin Elmer). Luminescent emission was stimulated by adding 5 mM
Coelenterazine and signal collected with the Victor3 plate reader (Perkin
Elmer). Please refer to Extended Experimental Procedures for details.
Bioinformatic Analysis
We used tissue samples from The Cancer Genome Atlas (TCGA) project to
assess relationships between PTENmutation status, PTEN copy number sta-
tus, and expression levels of AKT and pAKT in human cancer samples. Please
refer to Extended Experimental Procedures for details.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Extended Experimental Procedures and
seven figures and can be found with this article online at http://dx.doi.org/
10.1016/j.cell.2014.03.027.
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